2020 Q4 Form 10-K Financial Statement
#000143774921006778 Filed on March 22, 2021
Income Statement
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| Revenue | $24.71M | $21.71M |
| YoY Change | 13.82% | 23.61% |
| Cost Of Revenue | $9.715M | $8.763M |
| YoY Change | 10.86% | 15.45% |
| Gross Profit | $15.00M | $12.95M |
| YoY Change | 15.83% | 29.82% |
| Gross Profit Margin | 60.69% | 59.64% |
| Selling, General & Admin | $12.70M | $10.36M |
| YoY Change | 22.6% | 20.33% |
| % of Gross Profit | 84.7% | 80.02% |
| Research & Development | ||
| YoY Change | ||
| % of Gross Profit | ||
| Depreciation & Amortization | $3.533M | $1.276M |
| YoY Change | 176.88% | 3.15% |
| % of Gross Profit | 23.56% | 9.86% |
| Operating Expenses | $13.96M | $11.64M |
| YoY Change | 19.98% | 18.17% |
| Operating Profit | $1.035M | $1.311M |
| YoY Change | -21.05% | 940.48% |
| Interest Expense | -$237.0K | -$468.0K |
| YoY Change | -49.36% | 6.61% |
| % of Operating Profit | -22.9% | -35.7% |
| Other Income/Expense, Net | -$9.000K | -$26.00K |
| YoY Change | -65.38% | 44.44% |
| Pretax Income | $789.0K | $817.0K |
| YoY Change | -3.43% | -346.83% |
| Income Tax | -$9.881M | $12.00K |
| % Of Pretax Income | -1252.34% | 1.47% |
| Net Earnings | $10.67M | $805.0K |
| YoY Change | 1225.47% | -392.73% |
| Net Earnings / Revenue | 43.18% | 3.71% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | $486.0K | $36.85K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 20.24M | 19.84M |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $9.648M | $2.647M |
| YoY Change | 264.49% | -38.7% |
| Cash & Equivalents | $9.648M | $2.647M |
| Short-Term Investments | ||
| Other Short-Term Assets | $2.402M | $1.662M |
| YoY Change | 44.52% | 21.14% |
| Inventory | $3.001M | $2.899M |
| Prepaid Expenses | ||
| Receivables | $14.72M | $12.10M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $29.77M | $19.31M |
| YoY Change | 54.21% | 10.08% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $4.296M | $4.037M |
| YoY Change | 6.42% | 179.38% |
| Goodwill | $0.00 | |
| YoY Change | ||
| Intangibles | $11.18M | $15.46M |
| YoY Change | -27.72% | -22.16% |
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $105.0K | $155.0K |
| YoY Change | -32.26% | 13.14% |
| Total Long-Term Assets | $67.22M | $59.92M |
| YoY Change | 12.18% | 28.76% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $29.77M | $19.31M |
| Total Long-Term Assets | $67.22M | $59.92M |
| Total Assets | $96.99M | $79.22M |
| YoY Change | 22.43% | 23.65% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $6.779M | $7.962M |
| YoY Change | -14.86% | 12.28% |
| Accrued Expenses | $1.411M | |
| YoY Change | ||
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $9.423M | $8.082M |
| YoY Change | 16.59% | 64.84% |
| Total Short-Term Liabilities | $23.00M | $21.85M |
| YoY Change | 5.26% | 47.71% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $29.38M | $30.30M |
| YoY Change | -3.03% | 5.04% |
| Other Long-Term Liabilities | $3.864M | $4.644M |
| YoY Change | -16.8% | |
| Total Long-Term Liabilities | $29.38M | $30.30M |
| YoY Change | -3.03% | -30.57% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $23.00M | $21.85M |
| Total Long-Term Liabilities | $29.38M | $30.30M |
| Total Liabilities | $56.24M | $56.89M |
| YoY Change | -1.14% | 30.39% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$44.04M | -$61.37M |
| YoY Change | -28.24% | -2.17% |
| Common Stock | $2.000K | $2.000K |
| YoY Change | 0.0% | 0.0% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $40.75M | $22.33M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $96.99M | $79.22M |
| YoY Change | 22.43% | 23.65% |
Cashflow Statement
| Concept | 2020 Q4 | 2019 Q4 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | $10.67M | $805.0K |
| YoY Change | 1225.47% | -392.73% |
| Depreciation, Depletion And Amortization | $3.533M | $1.276M |
| YoY Change | 176.88% | 3.15% |
| Cash From Operating Activities | $7.612M | $4.341M |
| YoY Change | 75.35% | 36.47% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | -$4.094M | -$6.175M |
| YoY Change | -33.7% | 63.27% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $882.0K | $713.0K |
| YoY Change | 23.7% | -26.87% |
| Cash From Investing Activities | -$3.212M | -$5.462M |
| YoY Change | -41.19% | 94.58% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 3.309M | 611.0K |
| YoY Change | 441.57% | 885.48% |
| NET CHANGE | ||
| Cash From Operating Activities | 7.612M | 4.341M |
| Cash From Investing Activities | -3.212M | -5.462M |
| Cash From Financing Activities | 3.309M | 611.0K |
| Net Change In Cash | 7.709M | -510.0K |
| YoY Change | -1611.57% | -216.97% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $7.612M | $4.341M |
| Capital Expenditures | -$4.094M | -$6.175M |
| Free Cash Flow | $11.71M | $10.52M |
| YoY Change | 11.32% | 51.03% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
| CY2020 | dei |
Entity Small Business
EntitySmallBusiness
|
true | |
| CY2020 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
| CY2020 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
| CY2020 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001337013 | |
| CY2021Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
20336671 | |
| CY2020 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
| CY2020 | dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | |
| CY2020 | dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | |
| CY2020 | dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | |
| CY2020Q2 | dei |
Entity Public Float
EntityPublicFloat
|
150739346 | |
| CY2020 | dei |
Entity Registrant Name
EntityRegistrantName
|
InfuSystem Holdings, Inc | |
| CY2020 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2020 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
| CY2020 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
| CY2020 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2020 | |
| CY2020 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-12-31 | |
| CY2020 | dei |
Document Type
DocumentType
|
10-K | |
| CY2020 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 per share | |
| CY2020 | dei |
Trading Symbol
TradingSymbol
|
infu | |
| CY2020 | infu |
Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
|
||
| CY2019 | infu |
Deferred Tax Assets Valuation Allowance Expense
DeferredTaxAssetsValuationAllowanceExpense
|
||
| CY2020 | infu |
Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
|
11250000 | |
| CY2019 | infu |
Deferred Tax Assets Valuation Allowance Release
DeferredTaxAssetsValuationAllowanceRelease
|
120000 | |
| CY2020 | infu |
Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
|
8900000 | |
| CY2019 | infu |
Depreciation Expense Related To Medical Equipment
DepreciationExpenseRelatedToMedicalEquipment
|
7500000 | |
| CY2020 | infu |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.084 | |
| CY2019 | infu |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.058 | |
| CY2014Q2 | infu |
Employee Stock Ownership Plan Esop Purchase Per Employee Maximum
EmployeeStockOwnershipPlanESOPPurchasePerEmployeeMaximum
|
25000 | |
| CY2020Q4 | infu |
Remaining Preownership Net Operating Loss Carryforwards
RemainingPreownershipNetOperatingLossCarryforwards
|
4500000 | |
| CY2014Q2 | infu |
Employee Stock Purchase Plan Discount Rate
EmployeeStockPurchasePlanDiscountRate
|
0.15 | |
| CY2020 | infu |
Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
|
7.43 | |
| CY2019 | infu |
Employee Stock Purchase Plan Weighted Average Purchase Price Of Shares Purchased
EmployeeStockPurchasePlanWeightedAveragePurchasePriceOfSharesPurchased
|
3.94 | |
| CY2020Q4 | infu |
Longterm Debt Maturities Repayments Of Principal Year Four And Thereafter
LongtermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter
|
||
| CY2020Q4 | infu |
Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
|
33000 | |
| CY2019Q4 | infu |
Medical Equipment For Sale Or Rental Reserve
MedicalEquipmentForSaleOrRentalReserve
|
28000 | |
| CY2020Q4 | infu |
Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
|
1603000 | |
| CY2019Q4 | infu |
Medical Equipment Held For Sale Or Rental
MedicalEquipmentHeldForSaleOrRental
|
1306000 | |
| CY2020Q4 | infu |
Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
|
1636000 | |
| CY2019Q4 | infu |
Medical Equipment Held For Sale Or Rental Gross
MedicalEquipmentHeldForSaleOrRentalGross
|
1334000 | |
| CY2020Q4 | infu |
Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
|
35611000 | |
| CY2019Q4 | infu |
Medical Equipment In Rental Service Net Of Accumulated Depreciation
MedicalEquipmentInRentalServiceNetOfAccumulatedDepreciation
|
33225000 | |
| CY2020Q4 | infu |
Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
|
46907000 | |
| CY2019Q4 | infu |
Medical Equipment In Rental Services Accumulated Depreciation
MedicalEquipmentInRentalServicesAccumulatedDepreciation
|
41908000 | |
| CY2020Q4 | infu |
Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
|
83411000 | |
| CY2019Q4 | infu |
Medical Equipment In Rental Services Gross
MedicalEquipmentInRentalServicesGross
|
75853000 | |
| CY2020Q4 | infu |
Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
|
893000 | |
| CY2019Q4 | infu |
Medical Equipment In Rental Services Reserve
MedicalEquipmentInRentalServicesReserve
|
720000 | |
| CY2020 | infu |
Medical Equipment In Rental Services Useful Life
MedicalEquipmentInRentalServicesUsefulLife
|
P7Y | |
| CY2020Q4 | infu |
Medical Equipment Net
MedicalEquipmentNet
|
37214000 | |
| CY2019Q4 | infu |
Medical Equipment Net
MedicalEquipmentNet
|
34531000 | |
| CY2020 | infu |
Net Operating Loss Carryforwards Limitation On Use
NetOperatingLossCarryforwardsLimitationOnUse
|
1800000 | |
| CY2019Q4 | infu |
Number Of Financial Institutions
NumberOfFinancialInstitutions
|
2 | |
| CY2020 | infu |
Number Of Leases Entered Into During The Period For Equipment
NumberOfLeasesEnteredIntoDuringThePeriodForEquipment
|
4 | |
| CY2020Q4 | infu |
Number Of Operating Locations
NumberOfOperatingLocations
|
5 | |
| CY2020 | infu |
Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
|
15820000 | |
| CY2019 | infu |
Payments To Acquire Medical Equipment
PaymentsToAcquireMedicalEquipment
|
19669000 | |
| CY2020 | infu |
Reductions To Right Of Use Assets Resulting From Reductions To Lease Obligations
ReductionsToRightOfUseAssetsResultingFromReductionsToLeaseObligations
|
||
| CY2019 | infu |
Reductions To Right Of Use Assets Resulting From Reductions To Lease Obligations
ReductionsToRightOfUseAssetsResultingFromReductionsToLeaseObligations
|
22000 | |
| CY2020 | infu |
Revenues External
RevenuesExternal
|
97388000 | |
| CY2019 | infu |
Revenues External
RevenuesExternal
|
81115000 | |
| CY2020 | infu |
Revenues Internal
RevenuesInternal
|
||
| CY2019 | infu |
Revenues Internal
RevenuesInternal
|
||
| CY2020Q4 | infu |
Stock Issued During Period Shares Employee Stock Ownership Plan Number Of Remaining Shares Available For Future Issuance
StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance
|
187676 | |
| CY2020Q4 | infu |
Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
|
17000 | |
| CY2019Q4 | infu |
Unamortized Debt Issuance Expense Current
UnamortizedDebtIssuanceExpenseCurrent
|
17000 | |
| CY2020Q4 | infu |
Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
|
49000 | |
| CY2019Q4 | infu |
Unamortized Debt Issuance Expense Noncurrent
UnamortizedDebtIssuanceExpenseNoncurrent
|
66000 | |
| CY2020Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal Current
UnamortizedValueOfDebtIssuanceCostsPrincipalCurrent
|
17000 | |
| CY2020Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Four
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFour
|
15000 | |
| CY2020Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Four And Thereafter
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFourAndThereafter
|
||
| CY2020Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Three
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearThree
|
17000 | |
| CY2020Q4 | infu |
Unamortized Value Of Debt Issuance Costs Principal In Year Two
UnamortizedValueOfDebtIssuanceCostsPrincipalInYearTwo
|
17000 | |
| CY2020Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6779000 | |
| CY2019Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7962000 | |
| CY2020Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
14720000 | |
| CY2019Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
12097000 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2979000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2648000 | |
| CY2020Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
84785000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
83699000 | |
| CY2019 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
717000 | |
| CY2020 | us-gaap |
Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
|
1714000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
113000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
190000 | |
| CY2019 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
997000 | |
| CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2610000 | |
| CY2020Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
1000000 | |
| CY2019Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
|
400000 | |
| CY2020 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
17000 | |
| CY2019 | us-gaap |
Amortization Of Financing Costs
AmortizationOfFinancingCosts
|
37000 | |
| CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4285000 | |
| CY2019 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4402000 | |
| CY2020Q4 | us-gaap |
Assets
Assets
|
96991000 | |
| CY2019Q4 | us-gaap |
Assets
Assets
|
79224000 | |
| CY2020Q4 | us-gaap |
Assets Current
AssetsCurrent
|
29771000 | |
| CY2019Q4 | us-gaap |
Assets Current
AssetsCurrent
|
19305000 | |
| CY2020 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div></div> <div style="display: inline; font-weight: bold;">Basis of Presentation and Nature of Operations</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">InfuSystem Holdings, Inc. and its consolidated subsidiaries (the “Company”) are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from <div style="display: inline; font-style: italic; font: inherit;">five</div> locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem Inc. (“ISI”), which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc. (First Biomedical), which is an operating subsidiary of the Company, is ISO certified.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company's core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company's pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supplied more than <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">10%</div></div> of the ambulatory pumps purchased by the Company in <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The Company has a supply agreement in place with each of these suppliers. Certain “spot” purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (“NPWT”) medical equipment, as well as related disposables and ancillary supplies. Cardinal Health, Inc. supplied more than <div style="display: inline; font-style: italic; font: inherit;">10%</div> of the NPWT medical equipment purchased by the Company in <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The Company has a supply agreement in place with Cardinal Health, Inc.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company's ambulatory infusion pump management service.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).</div></div> | |
| CY2020 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
793000 | |
| CY2019 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2773000 | |
| CY2020 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
1900000 | |
| CY2019 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
2000000 | |
| CY2019Q4 | us-gaap |
Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
|
0 | |
| CY2020Q4 | us-gaap |
Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
|
0 | |
| CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9648000 | |
| CY2019Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2647000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
2647000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
4318000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
9648000 | |
| CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
7001000 | |
| CY2019 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-1671000 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | |
| CY2019Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
11250000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23816193 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23400625 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
20297704 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
19882136 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2020 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company's largest contracted payer was a national payer which accounted for approximately <div style="display: inline; font-style: italic; font: inherit;">14%</div> and <div style="display: inline; font-style: italic; font: inherit;">8%</div> of ITS net revenues for <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively, and approximately <div style="display: inline; font-style: italic; font: inherit;">9%</div> and <div style="display: inline; font-style: italic; font: inherit;">5%</div> of total consolidated net revenues for <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"> </div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company also contracts with various other <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above, <div style="display: inline; font-style: italic; font: inherit;">no</div> other single payer represented more than <div style="display: inline; font-style: italic; font: inherit;">7%</div> of the Company's ITS net revenue.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2020 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
38629000 | |
| CY2019 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
34233000 | |
| CY2020 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
11000 | |
| CY2019 | us-gaap |
Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
|
||
| CY2020 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
205000 | |
| CY2019 | us-gaap |
Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
|
30000 | |
| CY2020 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
66000 | |
| CY2019 | us-gaap |
Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
|
29000 | |
| CY2020 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
-8346000 | |
| CY2019 | us-gaap |
Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
|
104000 | |
| CY2020Q4 | us-gaap |
Deferred Finance Costs Net
DeferredFinanceCostsNet
|
66000 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
9967000 | |
| CY2019Q4 | us-gaap |
Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
|
||
| CY2020 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
-10071000 | |
| CY2019 | us-gaap |
Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
|
104000 | |
| CY2020Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
||
| CY2019Q4 | us-gaap |
Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
|
104000 | |
| CY2020 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
-1725000 | |
| CY2019 | us-gaap |
Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
|
||
| CY2020Q4 | us-gaap |
Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
|
9967000 | |
| CY2018Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
11370000 | |
| CY2020Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
||
| CY2019Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
104000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
548000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
3930000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
367000 | |
| CY2020 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
800000 | |
| CY2019 | us-gaap |
Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
|
700000 | |
| CY2020 | us-gaap |
Depreciation
Depreciation
|
9740000 | |
| CY2019 | us-gaap |
Depreciation
Depreciation
|
7940000 | |
| CY2020 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
14025000 | |
| CY2019 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
12342000 | |
| CY2020 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
800000 | |
| CY2019 | us-gaap |
Depreciation Nonproduction
DepreciationNonproduction
|
500000 | |
| CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.86 | |
| CY2019 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
0.07 | |
| CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.80 | |
| CY2019 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
0.07 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
-1.298 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.107 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.21 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-1.492 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.079 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.002 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
|
0.02 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.015 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.006 | |
| CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.051 | |
| CY2019 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.02 | |
| CY2020 | us-gaap |
Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
|
108589 | |
| CY2019 | us-gaap |
Employee Stock Ownership Plan Esop Compensation Expense
EmployeeStockOwnershipPlanESOPCompensationExpense
|
43030 | |
| CY2014Q2 | us-gaap |
Employee Stock Ownership Plan Esop Shares Contributed To Esop
EmployeeStockOwnershipPlanESOPSharesContributedToESOP
|
200000 | |
| CY2020 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
-8335000 | |
| CY2019 | us-gaap |
Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
|
104000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
38610000 | |
| CY2019Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
34324000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
1733000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
548000 | |
| CY2020Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
2051000 | |
| CY2020 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
3577000 | |
| CY2019 | us-gaap |
Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
|
1453000 | |
| CY2020 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
35195000 | |
| CY2019 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
28986000 | |
| CY2020 | us-gaap |
Gross Profit
GrossProfit
|
58759000 | |
| CY2019 | us-gaap |
Gross Profit
GrossProfit
|
46882000 | |
| CY2020 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | |
| CY2019 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
0 | |
| CY2020Q4 | us-gaap |
Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
|
0 | |
| CY2020 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2019 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
0 | |
| CY2020 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
418000 | |
| CY2019 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
638000 | |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
6623000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
1413000 | |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
7543000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
1524000 | |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
920000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
111000 | |
| CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
7543000 | |
| CY2019 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
|
1524000 | |
| CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
-9789000 | |
| CY2019 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
163000 | |
| CY2020 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
102000 | |
| CY2019 | us-gaap |
Income Taxes Paid
IncomeTaxesPaid
|
111000 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
2394000 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
|
2436000 | |
| CY2020 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
2631000 | |
| CY2019 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1560000 | |
| CY2020 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
102000 | |
| CY2019 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
645000 | |
| CY2020 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
740000 | |
| CY2020Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
96991000 | |
| CY2019Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
100000 | |
| CY2020Q4 | us-gaap |
Inventory Valuation Reserves
InventoryValuationReserves
|
100000 | |
| CY2020 | us-gaap |
Lease Cost
LeaseCost
|
1932000 | |
| CY2019 | us-gaap |
Lease Cost
LeaseCost
|
2239000 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
79224000 | |
| CY2019 | us-gaap |
Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
|
290000 | |
| CY2020 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
186000 | |
| CY2019 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
129000 | |
| CY2020 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1610276 | |
| CY2019 | us-gaap |
Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
|
1107898 | |
| CY2020Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
49787000 | |
| CY2019Q4 | us-gaap |
Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
|
49787000 | |
| CY2020Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
11177000 | |
| CY2019Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
15463000 | |
| CY2020 | us-gaap |
Interest Expense
InterestExpense
|
1255000 | |
| CY2019 | us-gaap |
Interest Expense
InterestExpense
|
1904000 | |
| CY2020 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1214000 | |
| CY2019 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1705000 | |
| CY2020Q4 | us-gaap |
Inventory Net
InventoryNet
|
3001000 | |
| CY2019Q4 | us-gaap |
Inventory Net
InventoryNet
|
2899000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
7210000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
2253000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
1108000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
914000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
949000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
941000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
1045000 | |
| CY2020Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
2380000 | |
| CY2020Q4 | us-gaap |
Liabilities
Liabilities
|
56239000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
56890000 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
22997000 | |
| CY2019Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
21847000 | |
| CY2020Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
38801000 | |
| CY2019Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
38377000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
9423000 | |
| CY2019Q4 | us-gaap |
Long Term Debt Current
LongTermDebtCurrent
|
8082000 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y146D | |
| CY2019Q4 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | |
| CY2020 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
2 | |
| CY2020 | us-gaap |
Operating Expenses
OperatingExpenses
|
49932000 | |
| CY2019 | us-gaap |
Operating Expenses
OperatingExpenses
|
43357000 | |
| CY2020 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
8827000 | |
| CY2019 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
3525000 | |
| CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1617000 | |
| CY2019 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1948000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
9423000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
12760000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
8198000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
8420000 | |
| CY2020Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
29378000 | |
| CY2019Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
30295000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-1117000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
4097000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-12162000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-19643000 | |
| CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
20280000 | |
| CY2019 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
13875000 | |
| CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
17332000 | |
| CY2019 | us-gaap |
Net Income Loss
NetIncomeLoss
|
1361000 | |
| us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | ||
| CY2020Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
4830000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
3864000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
4644000 | |
| CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1603000 | |
| CY2019 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1610000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
4461000 | |
| CY2019Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
5733000 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.078 | |
| CY2019Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.077 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y | |
| CY2020Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
2402000 | |
| CY2019Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
1662000 | |
| CY2019 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
2952000 | |
| CY2020 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
190000 | |
| CY2019 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
252000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
7275000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
105000 | |
| CY2019Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
155000 | |
| CY2020Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
6795000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
5803000 | |
| CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-29000 | |
| CY2019 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-97000 | |
| CY2020 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
||
| CY2019 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
6000 | |
| CY2020 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
1714000 | |
| CY2019 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
717000 | |
| CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1094000 | |
| CY2019 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
2926000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.0001 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
1000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Reclassifications</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders' equity as previously reported.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2020 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
37587000 | |
| CY2019 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
9436000 | |
| CY2020 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
4752000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
6685000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4296000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
4037000 | |
| CY2020 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
791000 | |
| CY2019 | us-gaap |
Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
|
37000 | |
| CY2020 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
37180000 | |
| CY2019 | us-gaap |
Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
|
4868000 | |
| CY2020 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
1687000 | |
| CY2019 | us-gaap |
Restricted Stock Expense
RestrictedStockExpense
|
190000 | |
| CY2020Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-44035000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-61367000 | |
| CY2020 | us-gaap |
Revenues
Revenues
|
97388000 | |
| CY2019 | us-gaap |
Revenues
Revenues
|
81115000 | |
| CY2020 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
264000 | |
| CY2019 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
4545000 | |
| CY2020 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
9661000 | |
| CY2019 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
9932000 | |
| CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2610000 | |
| CY2019 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
997000 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
3.87 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
|
1.61 | |
| CY2016Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
|
350000 | |
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y91D | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P4Y229D | |
| CY2020 | us-gaap |
Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
|
100000 | |
| CY2019 | us-gaap |
Shares Paid For Tax Withholding For Share Based Compensation
SharesPaidForTaxWithholdingForShareBasedCompensation
|
100000 | |
| CY2020 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
-1659000 | |
| CY2019 | us-gaap |
State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
|
29000 | |
| CY2020 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
30012 | |
| CY2019 | us-gaap |
Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
|
33742 | |
| CY2020 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
||
| CY2019 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
139000 | |
| CY2020 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
||
| CY2020 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
923000 | |
| CY2019 | us-gaap |
Stock Option Plan Expense
StockOptionPlanExpense
|
807000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
20441000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22334000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
40752000 | |
| CY2020Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
66000 | |
| CY2019Q4 | us-gaap |
Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
|
83000 | |
| CY2019Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
0 | |
| CY2020 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> | |
| CY2020Q4 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
-11200000 | |
| CY2020 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
315000 | |
| CY2019 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
291000 | |
| CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
21717216 | |
| CY2019 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
20839396 | |
| CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
20106940 | |
| CY2019 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
19731498 |
